首页> 外国专利> THE USE OF RHAMNOLIPIDS AS A DRUG OF CHOICE IN THE CASE OF NUCLEAR DISASTERS IN THE TREATMENT OF THE COMBINATION RADIATION INJURIES AND ILLNESSES IN HUMANS AND ANIMALS

THE USE OF RHAMNOLIPIDS AS A DRUG OF CHOICE IN THE CASE OF NUCLEAR DISASTERS IN THE TREATMENT OF THE COMBINATION RADIATION INJURIES AND ILLNESSES IN HUMANS AND ANIMALS

机译:鼠李糖脂作为治疗核辐射的首选药物,用于治疗人类和动物的混合辐射损伤和疾病

摘要

This invention is related to the use of one or more rhamnmolipids based on structure Formula 1 where the composition of the mixture is useful in the treatment of combination radiation illnesses and regeneration of cells and/or tissues by different application ways of any desirable mentioned rhamnolipids. These rhamnolipid composition mixture are very suitable in the treatment of combination radiation injuries and illnesses and for the regeneration of human and animal cells and tissues after nuclear catastrophes; comprising two or more injuries/illnesses and for cell and tissue regenerations which include radiation damages combined with burns, mechanical injuries, infections of digestive system, infections of lungs, neutropenia, sepsis, atherosclerosis, depression, schizophrenia, atopic eczema and other illnesses in connection with radiation injuries.
机译:本发明涉及一种或多种基于结构式1的鼠李糖脂的用途,其中混合物的组成可用于通过任何所需提及的鼠李糖脂的不同施用方式来治疗合并放射疾病和细胞和/或组织的再生。这些鼠李糖脂组合物混合物非常适合于治疗放射线损伤和疾病,以及核灾难后人类和动物细胞与组织的再生。包括两种或多种伤害/疾病,并用于细胞和组织再生,包括辐射损伤并伴有烧伤,机械损伤,消化系统感染,肺部感染,中性粒细胞减少症,败血症,动脉粥样硬化,抑郁症,精神分裂症,特应性湿疹和其他相关疾病受到辐射伤害。

著录项

  • 公开/公告号WO2011109200A2

    专利类型

  • 公开/公告日2011-09-09

    原文格式PDF

  • 申请/专利权人 PILJAC GORAN;

    申请/专利号WO2011US25843

  • 发明设计人 PILJAC GORAN;

    申请日2011-02-23

  • 分类号A61K31/7028;A61K31/70;A61K31/715;A61K9/06;A61K9/16;A61K9/107;A61P17/02;A61P17;

  • 国家 WO

  • 入库时间 2022-08-21 17:55:49

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号